Trials / Completed
CompletedNCT00950638
A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
A Phase I Study to Establish the Safety and Tolerability of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Ophthotech Corporation · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are to evaluate the safety and tolerability of ARC1905 intravitreous injection in subjects with geographic atrophy secondary to dry age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avacincaptad Pegol | intravitreal injection |
Timeline
- Start date
- 2009-07-16
- Primary completion
- 2011-03-24
- Completion
- 2011-03-24
- First posted
- 2009-08-03
- Last updated
- 2025-03-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00950638. Inclusion in this directory is not an endorsement.